| Officials Present Family Of Local Soldier With Suicide Prevention Bill
Local soldiers are on a mission to support the family of a fallen member of their unit. On November 5th, President Bush signed the Joshua Omvig Suicide Prevention bill. Omvig was a member of the 339th Military Police Company, based in Davenport, when he committed suicide after returning from Iraq. Today, 15 members of the 339th headed to Des Moines to see Omvigs parents formally receive a copy of the bill. The law provides that soldiers who return from war are properly screened and treated for mental health problems, like Post Traumatic Stress Disorder. More tools and resources will now be available for soldiers. The hope is to help them before they might become suicidal. Sergeant First Class, Jennifer Buntemeyer, is among those making the trip, " Specialist Omvig was a great member in the unit and it's sad that he lost is internal war when he came back from Iraq.
Insulting British callers make operators sick
British callers may be infuriated when they discover that the company they are telephoning has moved its customer service centre to India. But their frustration is as nothing compared with the heart attacks, ulcers and insomnia afflicting those on the other end of the line. .
Provocative survey ties soldiers' concussion symptoms to stress, depression
Some provocative research suggests that traumatic brain injury may not be quite the signature wound of the Iraq war that it's been thought to be. The study suggests post-traumatic stress and depression often play a role in the memory loss, irritability, sleeplessness and other problems plaguing thousands of soldiers returning from Iraq. Many troops have suffered mild blast-related concussions, but there is no easy way to separate which symptoms are due to physical damage and which are caused by the traumatic stress of war. Nonmilitary doctors who looked at the survey call it good news, since there are successful treatments for post-traumatic stress and depression. The study found that brain injury made traumatic stress more likely.
Shareholders sue Lilly over Zyprexa woes
Eli Lilly and Co. has paid more than $1 billion to settle legal battles over its top-selling drug Zyprexa, and it might have to write another large check soon. But a new lawsuit says the company should have known better. Two shareholders have accused Lilly executives and directors of recklessly disregarding risks posed by illegal drug marketing tactics, which have been alleged in lawsuits and newspaper articles. Lilly spokesman Phil Belt calls the lawsuit "groundless." But it is the latest in a string of challenges over Zyprexa, which has generated billions of dollars - and reams of litigation - for Lilly. Settling thousands of patient lawsuits over the drug, an anti-psychotic approved to treat schizophrenia, acute mania and bipolar disorder, has cost Lilly more than $1 billion.
Astrazeneca Submits Supplemental New Drug Applications For Seroquel XR ...
AstraZeneca announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
The bipolar mania submission is based on a clinical study of once-daily treatment with SEROQUEL XR, compared to placebo, with a primary endpoint of change in YMRS (Young Mania Rating Scale) total score (week 3), in 316 patients suffering from bipolar mania. The bipolar depression submission is supported by a clinical study of once-daily treatment with SEROQUEL XR, compared to placebo, with a primary endpoint of change from baseline in MADRS (Montgomery Asberg Depression Rating Scale) total score after 8 weeks of treatment, in 280 patients diagnosed with bipolar depression.
|
